Sign inCreate account

Report workspace tools

NCT02648347COMPLETEDanonymous

Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CORRECTION)

Sponsor

Source record

Akebia Therapeutics

Phase

Source record

Phase 3

Modality

AI-normalized

small molecule

Target

AI-normalized

Vadadustat

Indication / condition

AI-normalized

Anemia

Intervention

Source record

Vadadustat, Darbepoetin alfa

Source & freshness

Source record

NCT ID

NCT02648347

Original source

ClinicalTrials.gov

Source last updated

Jun 27, 2022

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02648347

Title

Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CORRECTION)

Sponsor

Akebia Therapeutics

Status

COMPLETED

Phase

Phase 3

Condition raw

Anemia

Condition normalized

Anemia

Modality raw

Anemia

Modality normalized

small molecule

Target raw

Vadadustat

Target normalized

Vadadustat

Interventions

Vadadustat, Darbepoetin alfa

Public preview

Source record

The clinical trial evaluated Vadadustat for treating anemia in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Conducted by Akebia Therapeutics, the study aimed to demonstrate the efficacy and safety of Vadadustat compared to Darbepoetin alfa.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CORRECTION)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02648347

Status

COMPLETED

Phase

Phase 3

Sponsor

Akebia Therapeutics

Executive brief

Investment-Ready Snapshot

The clinical trial evaluated Vadadustat for treating anemia in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Conducted by Akebia Therapeutics, the study aimed to demonstrate the efficacy and safety of Vadadustat compared to Darbepoetin alfa.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 27, 2022
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02648347

Indication

Anemia

Modality

small molecule

Target

Vadadustat

Intervention

Vadadustat, Darbepoetin alfa

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.